Spruce Biosciences, Inc. Debt Securities, Available-for-sale, Amortized Cost
Spruce Biosciences, Inc. (SPRB) had Debt Securities, Available-for-sale, Amortized Cost of $105.05 million as of 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2024-03-18
- 2023-09-30: Debt Securities, Available-for-sale, Amortized Cost $105.05M.
- 2023-06-30: Debt Securities, Available-for-sale, Amortized Cost $118.14M.
- 2023-03-31: Debt Securities, Available-for-sale, Amortized Cost $115.86M.
- 2022-12-31: Debt Securities, Available-for-sale, Amortized Cost $77.64M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2023-09-30 | $105.05M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $118.14M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $115.86M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $77.64M 10-K · filed 2024-03-18 |
| 2022-09-30 | $87.38M 10-Q · filed 2022-11-10 |
| 2021-12-31 | $116.93M 10-K · filed 2023-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |